Clinical studies demonstrated strong activity of the BTK inhibitor ibrutinib and the mTOR inhibitor temsirolimus in subsets of MCL (23, 37), and our finding reveals potential biomarkers for treatment. This evidence concerns the gene MTOR and mantle cell lymphoma.